AANG: A natural compound formulation for targeting macrophage-myofibroblast transition in non-small-cell lung carcinoma
Year: 2026
Type: article
Abstract: Cancer-associated fibroblasts (CAFs) are major components of the tumor microenvironment (TME). They are highly heterogeneous containing both anti-cancer and pro-tumor populations, which largely limits their translational development. Recently, we have identified macrophage-myofibroblast transition (MMT) as a novel and key origin of pro-tumoral CAF in non-small-cell lung cancer (NSCLC), targeting it with Traditional Chinese Medicine (TCM) may represent a safe and effective strategy for solid tumors. Here, by spatial single-cell bioinformatics, we revealed that not only Smad3 activation but also Smad7 reduction occurs in the macrophages undergoing MMT in clinical NSCLC. Therefore, we optimized our well-established TCM-derived natural product formulation AANG, which remodulated TGF-β1/Smad3/Smad7 signaling and synergistically blocked MMT on the bone marrow derived macrophages (BMDM) in vitro. More encouragingly, this optimized AANG can effectively block MMT-derived cancer progression on mouse cancer models with syngeneic lung cancer LLC and human NSCLC xenograft A549 without side-effect in vivo. Thus, AANG may represent the first natural compound formulation for blocking MMT-derived pro-tumoral CAF formation in the clinical NSCLC.
Source: Phytomedicine
Language: English
Topic: TGF-β signaling in diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,630
Awards: G1162760586, G239154067, Development of A Novel Anticancer T Cell Origin for Effective Solid Cancer Immunotherapy: DCT, G5191908865, Development and Preclinical Evaluation of a Novel Macrophage-Myofibroblast Transition Targeted Therapy for Chronic Kidney Disease, G7598496863, Development and preclinical evaluation of a novel mincle targeted therapy for macrophage driven acute kidney injury, G8121569757
OpenAlex ID: W7128067299
